Welcome to the Starpharma Investor CentreStarpharma Holdings Limited is an Australian stock exchange listed biotechnology company with products based on its dendrimer technology platform. |
 |
|
|
Latest News & Announcements
Quarterly Activities Report & Appendix 4C (ASX Announcement)
Apr 30th, 2024
Starpharma (ASX: SPL, OTCQX: SPHRY), which is dedicated to enhancing the quality of life for patients with unmet medical needs, such as cancer, by creating innovative therapies using dendrimer technology, today releases its Quarterly Activities Report and Appendix 4C for the period ended 31 March 2024 (Q3 FY24). Starpharma’s closing cash balance as at 31 March 2024 was $26.6 million.
Read More
Investor Webinar - Starpharma and Medicxi Partnership: Petalion Therapeutics (9 April 2024)
Apr 10th, 2024
Starpharma hosted an investor webinar on Tuesday, 9 April 2024. The session focused on the ASX Announcement lodged on 8 April 2024, 'Starpharma and Medicxi Partnership Petalion Therapeutics', about the strategic partnership with Medicxi and the formation of a new company called Petalion Therapeutics.
Read More
Reports & Presentations
Click here for financial reports archive
Quarterly Activities Report & Appendix 4C (ASX Announcement)
Apr 30th, 2024
Starpharma (ASX: SPL, OTCQX: SPHRY), which is dedicated to enhancing the quality of life for patients with unmet medical needs, such as cancer, by creating innovative therapies using dendrimer technology, today releases its Quarterly Activities Report and Appendix 4C for the period ended 31 March 2024 (Q3 FY24). Starpharma’s closing cash balance as at 31 March 2024 was $26.6 million.
Read More
Which ASX companies are resurrecting abandoned drugs? Part 3
Apr 18th, 2024
"SPL has developed its proprietary Dendrimer Enhanced Products platform (DEP) to improve the effectiveness and safety of drugs, especially cancer treatments." Read the full article in Stockhead.
Read More